United Kingdom

People: ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

23 Aug 2019
Change (% chg)

$-0.34 (-3.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Pucci, Paolo 

Mr. Paolo Pucci is Chief Executive Officer, Director of the Company. he served as Senior Vice President and President in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Units. Previously, Mr. Pucci was senior vice president of Bayer Pharmaceuticals Global Specialty Business Unit, President of U.S. Pharmaceutical Operations and a member of the Bayer Pharmaceuticals Global Management Committee. At Bayer, Mr. Pucci was involved in a broad range of activities related to Nexavar® (sorafenib), an oral multiple kinase inhibitor used to treat liver and kidney cancers. These activities included clinical development, regulatory review, corporate alliance management, product launch and marketing. Mr. Pucci joined Bayer as head of its Italian Pharmaceutical operations in 2001. Prior to Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. At Lilly, his responsibilities included operations, sales, marketing and strategic planning. In November 2011, Mr. Pucci was appointed to the Board of Directors of Dyax Corp where he served as an independent director, member of the audit committee and chairman of the governance and nomination committee until the acquisition of Dyax by Shire in January 2016. In April 2013, he was appointed to the Board of Directors of Algeta ASA, an oncology company based in Oslo, Norway, where he served as an independent director and member of the audit committee until the acquisition of Algeta by Bayer A.G. He also served as a Director of NewLink Genetics Corp., from November 2015 to December 2018. During September 2016, Mr. Pucci was elected to the Board of Directors of West Pharmaceutical Services, Inc., an international manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Mr. Pucci holds an M.B.A from the University of Chicago and is a graduate of the Università Degli Studi Di Napoli in Naples, Italy.

Basic Compensation

Total Annual Compensation, USD 810,273
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 934,254
Fiscal Year Total, USD 1,744,530

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Patrick Zenner


Peter Lawrence


Paolo Pucci


Marc Schegerin


Brian Schwartz


Timothy Barabe

As Of  31 Dec 2018